Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
暂无分享,去创建一个
G. Morgan | R. Houlston | W. Gregory | M. Drayson | M. Jenner | F. Davies | G. Cook | G. Jackson | D. Cairns | S. Savola | M. Kaiser | A. Sherborne | B. Walker | D. Johnson | V. Shah | R. Owen | Amy L. Sherborne | E. Boyle | C. Pawlyn | S. Ellis | F. Davies | Dil B. Begum | G. Jackson | J. R. Jones | D. Begum | P. Proszek | David C. Johnson | Vallari Shah | Sidra Ellis | B. Walker | John R Jones
[1] S. Rajkumar,et al. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. , 2016, Blood.
[2] H. Goldschmidt,et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[3] M. O'sullivan,et al. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Goldschmidt,et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.
[5] A. Palumbo,et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[6] D. Vaux,et al. Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. , 2016, Cancer cell.
[7] H. Goldschmidt,et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Gordon Cook,et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Gregor Bieri,et al. β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis , 2015, Nature Medicine.
[10] Aspire Investigators,et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .
[11] Gordon Cook,et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.
[12] G. Morgan,et al. A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma , 2014, Genes, chromosomes & cancer.
[13] Michael L. Wang,et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.
[14] Anna Tramontano,et al. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors , 2014, Cancer cell.
[15] M. Kuehl,et al. Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB , 2014, Oncotarget.
[16] B. Barlogie,et al. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. , 2014, Blood.
[17] H. Goldschmidt,et al. IMWG consensus on risk stratification in multiple myeloma , 2014, Leukemia.
[18] R. Kyle,et al. An overview of the progress in the treatment of multiple myeloma , 2014, Expert review of hematology.
[19] S. Vincent Rajkumar,et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.
[20] M. Amiot,et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma , 2013, Leukemia.
[21] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[22] J. Carpten,et al. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma , 2013, Haematologica.
[23] G. Morgan,et al. Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment , 2013, Clinical Cancer Research.
[24] G. Morgan,et al. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR , 2013, Leukemia.
[25] M. Schmidt-Supprian,et al. A20 and CYLD Do Not Share Significant Overlapping Functions during B Cell Development and Activation , 2012, The Journal of Immunology.
[26] Sankar Ghosh,et al. NF-κB, the first quarter-century: remarkable progress and outstanding questions. , 2012, Genes & development.
[27] G. Morgan,et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial , 2011, Leukemia.
[28] G. Morgan,et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide‐based therapy , 2011, Genes, chromosomes & cancer.
[29] G. Morgan,et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial , 2011, The Lancet. Oncology.
[30] C. Harrison,et al. Evaluation of multiplex ligation‐dependent probe amplification as a method for the detection of copy number abnormalities in B‐cell precursor acute lymphoblastic leukemia , 2010, Genes, chromosomes & cancer.
[31] G. Morgan,et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.
[32] G. Morgan,et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance , 2010, Haematologica.
[33] G. Morgan,et al. Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome , 2010, Clinical Cancer Research.
[34] Cheng Li,et al. Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] L. Bruhn,et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.
[36] L. Staudt,et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.
[37] G. Ahmann,et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma , 2006, Leukemia.
[38] P. L. Bergsagel,et al. Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Bart Barlogie,et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.
[40] J. Crowley,et al. International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] P. Hinds,et al. Multiple Functions of D-Type Cyclins Can Antagonize pRb-Mediated Suppression of Proliferation , 2005, Cell cycle.
[42] Tony Reiman,et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.
[43] C. Bastard,et al. Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.